Iovance Biotherapeutics To Present Clinical Data For Tumor Infiltrating Lymphocyte Therapy At IASLC 2023 World Conference On Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) will present clinical and preclinical data for its tumor infiltrating lymphocyte (TIL) therapies at the IASLC 2023 World Conference on Lung Cancer. The presentations will include a multicenter phase II trial of LN-145 TIL cell therapy plus pembrolizumab in patients with ICI-naïve metastatic NSCLC and the successful generation of TIL for adoptive cell therapy from mesothelioma.
July 25, 2023 | 8:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Iovance Biotherapeutics will present important clinical and preclinical data for its TIL therapies at a major conference. This could potentially impact the company's stock positively if the data is well received.
Presenting clinical and preclinical data at a major conference can have a significant impact on a biotech company's stock. If the data presented by Iovance Biotherapeutics is well received, it could lead to increased confidence in the company's therapies, potentially leading to a rise in the stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100